Exit value; Telling questions

Having just sold one of his companies to Marion Merrell Dow and partnered another with Zeneca Group, Stephen Evans-Freke discussed with BioCentury his views on returning value to shareholders in biotech companies. In our continuing search for ways to explain The Clear Route to ROI, we think his comments on the basic arithmetic of value speak for themselves, and report them below

Read the full 628 word article

How to gain access

Continue reading with a
two-week free trial.